Cardiopulmonary Insights

News, strategy, and signals in PAH care.
Real-World Data Validates Inhaled Tyvaso in WHO Group 3 PH
Real-world study confirms Tyvaso’s benefit in WHO Group 3 PH, supporting potential expansion beyond PAH.
July 28, 2025
Remodulin Phase 3 Study NCT06237096 Initiated
United Therapeutics begins a Phase 3 trial of implantable Remodulin delivery to improve safety and convenience in PAH.
July 28, 2025
FDA Approves Opsynvi for PAH Treatment
FDA approves Opsynvi, the first fixed-dose combo of macitentan and tadalafil for PAH. Positioned to compete with Uptravi and Opsumit.
July 28, 2025